DEC 2 9 2086

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE flection of information unless it displays a valid OMB control number, Inder the Paperwork Reduction Act of 1995, no corson Application Number 10/078,949 Filing Date TRANSMITTAL 02/20/2002 First Named Inventor **FORM** Stanley T. Crooke Arl Unit 1835 Examiner Name Sean McGarry (to be used for all correspondence after initial filing) Attorney Docket Number ISIS-5027 18 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Fee Attached Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Preliminary Amendment Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please identify Terminal Disclaimer below): **Extension of Time Request** Request for Refund Exprese Abandonment Request CD, Number of CD(s)\_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parta/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Isis Pharmaceuticals, Inc. Signature ax Printed name Jødi L Connolly, Ph.D. Date Reg. No. 54.044 **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date 12000 Laura Eames Typed or printed name

This collection of Information is required by \$7 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by \$25 U.S.C. 122 and \$7 CFR 1.11 and 1.14. This collection is estimated to \$2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the inclinidate case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## **2**002/018

## RECEIVED **CENTRAL FAX CENTER**

DEC 2 9 2006

**DOCKET NO: ISIS-5027** 

APPLICANTS: Stanley T. Crooke SERIAL NO: 10/078,949

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.:

ISIS-5027

Customer No.:

32650

Applicant:

Stanley T. Crooke

Confirmation No.:

8454

Serial No.:

10/078,949

Group Art Unit:

1635

Filed:

February 20, 2002

Examiner:

Sean McGarry

Title:

OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING

RNA

I certify that this correspondence is being facsimile transmitted or is being deposited with the U.S. Postal Service as First Class mall in an envelope addressed to the Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450.

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Examiner:

## AMENDMENT AND REQUEST FOR RECONSIDERATION

In response to the Office Action dated June 23, 2006 and the notice of Non-Responsive Amendment dated December 6, 2006, reconsideration is respectfully requested in view of the following amendments and/or remarks.

Amendments to the Specification begin on page 2.

Amendments to the Claims are reflected in the listing of claims which begins on page 5.

Remarks begin on page 12.